PET-CT vs brain MRI for the detection of cerebral metastases of melanoma, a 5-year retrospective study.

Tutic-Sorrentino, Lisa; Cazzaniga, Simone; Feldmeyer, Laurence; Benzaquen, Michael Joseph (2024). PET-CT vs brain MRI for the detection of cerebral metastases of melanoma, a 5-year retrospective study. Clinical and Experimental Dermatology, 49(10), pp. 1179-1185. Blackwell Scientific Publications 10.1093/ced/llae129

[img]
Preview
Text
llae129.pdf - Accepted Version
Available under License Creative Commons: Attribution (CC-BY).

Download (505kB) | Preview

BACKGROUND

Melanoma patients present a high risk of developing extra cutaneous metastases. PET-CT is one of the preferred examinations for the staging of oncological patients. It is not the method of choice to detect brain metastases, but this technique has shown significant improvement and allows the detection of some of them, although it is unclear how it performs compared to the MRI, the current gold standard for diagnosing brain metastases.

OBJECTIVE

To compare the accuracy of PET-CT and cerebral MRI to detect brain metastases in melanoma patients.

METHODS

We retrospectively included all patients diagnosed with melanoma stage IIC-IV (AJCC 8th Edition-2017) presented at the skin tumor board of the University Hospital of Bern between 01/2018 and 12/2022. All radiological reports extracted from the patient management system were analyzed to assess a discrepancy between the visibility of brain metastases on PET-CT and brain MRI.

RESULTS

In this study including 393 patients, brain MRI demonstrated significantly higher performance than PET-CT in detecting brain metastases. Cerebral metastases were detected completely, partially or were not detected by PET-CT in respectively 2 patients (4%), 15 patients (32%) and 30 patients (64%) out of 47.

CONCLUSION

Despite the increasing performance of PET-CT, this study highlights the crucial role of brain MRI, which remains the gold standard to detect cerebral metastases. Brain MRI should be performed on patients with high-risk melanoma from stage IIC to exclude brain metastases.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Cazzaniga, Simone, Feldmeyer, Laurence, Benzaquen, Michael Joseph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0307-6938

Publisher:

Blackwell Scientific Publications

Language:

English

Submitter:

Pubmed Import

Date Deposited:

17 Apr 2024 08:23

Last Modified:

20 Sep 2024 00:12

Publisher DOI:

10.1093/ced/llae129

PubMed ID:

38624009

BORIS DOI:

10.48350/196021

URI:

https://boris.unibe.ch/id/eprint/196021

Actions (login required)

Edit item Edit item
Provide Feedback